Stay updated with breaking news from Xencor Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Xencor (NASDAQ:XNCR – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued on Thursday, RTT News reports. They presently have a $34.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $36.00. Wedbush’s price objective points to a potential upside […]
MorphoSys (NASDAQ:MOR – Get Free Report) and Graybug Vision (NASDAQ:GRAY – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations. Valuation & Earnings This table compares MorphoSys and Graybug […]
Aileron Therapeutics (NASDAQ:ALRN – Get Free Report) and Atreca (NASDAQ:BCEL – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk. Profitability This table compares Aileron Therapeutics and Atreca’s […]
Cannell & Co. purchased a new position in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 12,600 shares of the biopharmaceutical company’s stock, valued at approximately $267,000. Several other institutional investors have also […]
– Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver Congress 2024 – – Two additional hepatitis program data readouts...